Form 483

King Bio Inc Form 483, 2021-08-12

FDA issued a Form 483 to King Bio Inc on 2021-08-12 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

King Bio Inc · Asheville, United States · Issued August 12, 2021

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

12 Aug 2021
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Jared P Stevens, Bonita S Chester

12 Aug 2021
21 CFR 211.111

Establishment of time limitations

Cited by Jared P Stevens, Bonita S Chester

12 Aug 2021
21 CFR 211.184(c)

Individual inventory record

Cited by Jared P Stevens, Bonita S Chester

12 Aug 2021
21 CFR 211.192

Written record of investigation incomplete

Cited by Jared P Stevens, Bonita S Chester

12 Aug 2021
21 CFR 211.25(a)

Training--operations, GMPs, written procedures

Cited by Jared P Stevens, Bonita S Chester

Inspected site

KBKing Bio IncAsheville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.111Cited across public-safe Form 483 observations1x
21 CFR 211.184(c)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere